**Osteoporosis and fractures in women: the burden of disease**

1,2,3Mattias Lorentzon MD PhD, 1,3Helena Johansson PhD, 5,6Nicholas C Harvey MD PhD, 1Enwu Liu, 1,3Liesbeth Vandenput PhD, 7,8Eugene McCloskey MD PhD, 3,7John A Kanis MD, PhD

**Affiliations**

1Sahlgrenska Osteoporosis Centre, Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden.

2Region Västra Götaland, Department of Geriatric Medicine, Sahlgrenska University Hospital, Mölndal, Sweden.

3Mary MacKillop Institute for Health Research, Australian Catholic University, Melbourne, VIC, Australia.

5MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK.

6NIHR Southampton Biomedical Research Centre, University of Southampton and University Hospital Southampton NHS Foundation Trust, Tremona Road, Southampton, UK

7Centre for Metabolic Bone Diseases, University of Sheffield Medical School, UK.

8MRC and Arthritis Research UK Centre for Integrated Research in Musculoskeletal Ageing, Mellanby Centre for Bone Research, University of Sheffield, UK.

**Corresponding author:**

Mattias Lorentzon, Professor, MD

Geriatric Medicine, Institute of Medicine, University of Gothenburg, Sahlgrenska University Hospital Mölndal, 43180 Mölndal, Sweden

Email: mattias.lorentzon@acu.edu.au; [mattias.lorentzon@medic.gu.se](mailto:mattias.lorentzon@medic.gu.se)

**Disclosures**

Professor Lorentzon has received lecture fees from Amgen, Astellas, Lilly, Meda, Renapharma, UCB Pharma, and consulting fees from Amgen, Radius Health, UCB Pharma, Renapharma and Consilient Health. N. Harvey has received consultancy, lecture fees and honoraria from Alliance for Better Bone Health, AMGEN, MSD, Eli Lilly, Servier, Shire, UCB, Kyowa Kirin, Consilient Healthcare, Radius Health and Internis Pharma outside the scope of the submitted work. E McCloskey has received consultancy, research funding, lecture fees and/or honoraria from AgNovos, AgNovos, AstraZeneca, Consilient Healthcare, Fresenius Kabi, GSK, Hologic, Internis, Lilly, ObsEva, Synexus, UCB outside the scope of this work. All other authors have no conflicts of interest.

Word count: 2890

Abstract: 191

**Abstract**

Osteoporosis is a disease characterized by impaired bone microarchitecture and reduced bone mineral density (BMD) resulting in bone fragility and increased risk of fracture. In Western societies, 1 in 3 women and 1 in 5 men will sustain an osteoporotic fracture in their remaining lifetime from the age of 50 years. Fragility fractures, especially of the spine and hip, commonly give rise to increased morbidity and mortality. In the five largest European countries and Sweden, fragility fractures were the cause of 2.6 million disability-adjusted life years in 2016 and the fracture-related costs, increased from €29.6 billion in 2010 to €37.5 billion in 2017. In the European Union and the Unites States, only a small proportion of women eligible for pharmacological treatment are being prescribed osteoporosis medication. Secondary fracture prevention, using Fracture Liaison Services, can be used to increase the rates of fracture risk assessment, BMD testing, and use of osteoporosis medication in order to reduce fracture numbers. Additionally, established primary prevention strategies, based on case-finding methods utilizing fracture prediction tools, such as FRAX, to identify women without fracture, but with elevated risk, are recommended, in order to further reduce fracture numbers.

**Postmenopausal osteoporosis**

Osteoporosis is a disease characterized by impaired bone microarchitecture and reduced bone mineral density resulting in bone fragility and increased risk of fracture [1,2]. Bone mineral density (BMD) measured using dual-energy x-ray absorptiometry (DXA) to a large extent reflects bone strength [3], and for each standard deviation (SD) decrease in femoral neck BMD fracture risk is increased 2 to 3-fold [4] in postmenopausal women. In 1994, the World Health Organization defined osteoporosis using a BMD threshold of -2.5 SD or lower than the mean value for young adult women, referred to as a T-score of -2.5 SD or less. A measurement of BMD at the femoral neck, and derivation of the T-score using the NHANES III reference database with women aged 20-29 years, has been proposed as the reference standard for describing osteoporosis. However, other sites such as the total hip, lumbar spine and radius are frequently used in clinical practice [5,6]. Ageing leads to bone loss, and particularly the first few years after menopause represent a period of accelerated bone loss [7]. Thus, the prevalence of osteoporosis increases with age [2].

Densitometric osteoporosis is asymptomatic, as patients affected are unaware of the disease until they sustain a fragility fracture. Common fractures associated with low BMD include fractures of the spine, hip, forearm, proximal humerus, ribs, sternum, pelvis, sacrum and the clavicle, whilst fractures of the ankle, hands, feet and skull are to a lesser extent associated with BMD and generally not considered osteoporotic [8,9]. Overall, however, the majority of fractures in postmenopausal women are low-trauma fractures and fall into the osteoporotic category [2].

In Western societies, 1 in 3 women and 1 in 5 men, 50 years or older, will sustain an osteoporotic fracture in their remaining lifetime [10]. Many of these fractures have clinically important and sometimes severe consequences. Fractures, especially those of the spine and hip, often lead to functional decline, disability, chronic pain, reduced quality of life and increased morbidity and mortality [11-13]. Thus, osteoporotic fractures are common, have severe long-term consequences and therefore constitute a major public health concern.

**Prevalence of osteoporosis**

Using the femoral neck BMD definition of osteoporosis, a T-score of -2.5 SD or below, approximately 200 million women have osteoporosis globally [5,14]. As a result of BMD declining with age, the proportion of women having osteoporosis increases with age. At age 60 years, about 10% are affected, at age 70 about 20%, at 80 years approximately 40% and at age 90 years, as much as two thirds of all women have osteoporosis [15].

**Epidemiology of fractures**

In the year 2000, there were approximately 9 million new osteoporotic fractures worldwide, of which 1.7 were forearm fractures, 1.4 million were clinical vertebral fractures and 1.6 million were hip fractures [16]. In total, 51% of these fractures occurred in Europe and the Americas and the most of the remainder occurred in Southeast Asia and in the Western Pacific. In general, nearly twice as many fractures occur in women than in men, and in in the case of hip fractures, nearly 75% affect women [17].

As a result of age-dependent decline in BMD, increasing prevalence of sarcopenia, frailty and falls, the risk of fracture increases with age [2,18]. The incidence of vertebral fracture in women starts to rise at around age 60 years and accelerates to reach the highest levels after age 80 years. For hip fractures, the incidence in women starts to rise sharply after age 70 years with peak incidence rates above 80 years of age (Figure 1)[19].

Substantial differences in fracture rates between countries have been observed. The age standardized annual hip fracture rate per 100,000 women is the highest in the Scandinavian countries, reaching nearly 600 cases, as compared to the much lower rates around 300 cases in the United States and far fewer cases in many African countries [20](Figure 2). The reason for the large difference in incidence between countries cannot be explained by differences in BMD; proposed contributing factors include differences in body composition, levels of physical activity, socio-economic status, calcium intake and differences in sunlight exposure [21,22].

The lifetime risk of fracture also varies considerably according to country. For example, in Sweden, the lifetime probability of hip fracture has been estimated to be 22.8% in women after age 50 years. The corresponding probabilities for hip fracture for women in the United Kingdom, France, Spain and Germany are considerably lower, ranging from 10% to about 17% [23].

In comparison to other diseases and conditions, the health and social care burden consequent to osteoporotic fractures is substantial. Interestingly, the lifetime probability of major osteoporotic fracture for women in Europe is comparable to that of cardiovascular disease, which affects 29% of European women [24].

**Patient burden**

Fragility fractures in older women often lead to functional decline, disability, decreased quality of life, chronic pain and increased risk of morbidity and mortality [25-28]. As a consequence of most hip fractures occurring in often fragile women at an advanced age, usually after age 80 years, a considerable proportion of affected women need to move to residential care facilities due to increased frailty and functional loss after the hip fracture, leading to loss of autonomy [29].

The WHO’s standard method to measure burden of disease uses disability-adjusted life years (DALYs), which include both the sum of years of life lost (YLL) and the years lost (YLD) due to disability. The sum of DALYs in the entire population yields the gap (or burden) between the present health status of the population and an ideal disease-free population [30]. In the five largest European countries and Sweden (EU6), fragility fractures were the cause of 2.6 million DALYs in 2016. Average YLDs per 1000 people was much greater (15.1) than YLLs (5.5), suggesting that disability due to fracture is the major contributor to DALYs lost in osteoporosis [23]. The number of DALYs due to fragility fractures in the EU6 countries was compared to 16 other non-communicable diseases and was outranked only by ischemic heart disease, dementia and lung cancer (Figure 3)[23,31].

Patient burden can also be assessed using quality adjusted life years (QALYs) as the outcome, which quantifies a year of an individual’s life in relation to the average health-related quality of life (HRQoL) during a year. As a point of reference, 1 QALY is equal to one year spent in perfect health and 0.5 QALYs can be defined either as 6 months spent in perfect health or as 12 months lived at 50% of perfect health. QALYs are particularly useful in health-economic analyses and can be used to compare societal burden across many diseases. In 2017, QALYs lost per capita due to fragility fractures varied considerably within the EU6 countries, and ranged from 4.2 per 1000 people in Sweden to 2.1 per 1000 people in France [23]. For all EU6 countries together, the total health burden caused by fragility fractures was 1.02 million QALYs in 2017 [23].

**Fracture related costs**

The cost for fragility fractures is dependent on the need for surgical treatment, admission to hospital, length of stay and need for rehabilitation. Both short-term and long-term costs are incurred by fragility fractures. The length of stay after hip fracture varies considerably by country within the EU6, ranging from, 11.6 days in Sweden to 20.5 days in the United Kingdom [23]. In the EU6, the fracture-related costs, both direct and indirect, increased from €29.6 billion in 2010 to €37.5 billion in 2017 [23]. Hip fractures are the cause of the greatest disutility and highest costs of all fractures [32]. In a systematic review, including 130 studies globally, with over 670,000 hip fracture patients with patient level hip fracture costs, the total costs covering health care costs and social costs the first year after a hip fracture were evaluated. The total 12 month cost was $43,669 per hip fracture patient of which inpatient costs ($13,331) followed by rehabilitation care ($12,020) contributed the most [33].

**Projections**

Assuming that the current trends in fracture prevention will continue, and the general

population increases, with an ageing demographic, the hospital and societal cost of fragility fractures will continue to increase. In Asia and South America, both the age-standardized incidence rates of hip fractures and the number of hip fractures are increasing[34]. In many Western countries, the age-specific incidence of hip fracture has decreased during recent years but, due to the ageing population, the absolute number of hip fractures has increased and is expected to continue to rise over the next decades [34]. A recent study of the Norwegian population concluded that health lost to hip fractures will nearly double, from 32,850 DALYs in 2020 to 60,555 DALYs in 2040, leading to an increase in the overall cost of 65%, despite a continued decline in the age-specific hip fracture rate. In the EU6, the total number of new fractures between 2017 and 2030 was in recent analysis projected to increase from 2.7 million per year to 3.3 million in 2030, which equals an increase of 23.3%. In the same region, fracture-related costs are projected to increase to €47.4 billion in 2030 which would equal a 27% increase from the 2017 estimate [23].

**Preventing fractures**

*Osteoporosis medication*

Since the 1990s, a wide range of therapeutic options to treat osteoporosis and reduce fracture risk in postmenopausal women have been introduced (Table 1). Generic bisphosphonates taken once weekly (alendronate and risedronate) or once yearly (zoledronic acid) are most commonly used; they reduce the relative risk of hip and spine fracture by approximately 40% and 50-70%, respectively, and are available at a low cost [35-38]. Denosumab, a monoclonal antibody against RANKL, given as biannual injections, increases BMD more than the bisphosphonates and over longer time-periods, is at least equally effective in reducing the risk of fractures at the hip and spine, and is generally well tolerated [39,40].

In more recent years, anabolic agents, including teriparatide, abaloparatide and romosozumab, have been shown to provide greater increases in spine and hip BMD as well as more effective fracture prevention, than that which can be achieved with the bisphosphonates in postmenopausal women with vertebral fracture and low BMD [41-44]. In this group of patients, teriparatide for 24 months and romosozumab for 12 months (followed by alendronate for 12 months) reduced the risk of vertebral fractures over 24 months by 56% and 48% compared to risedronate and alendronate, respectively [45,46]. Based on these findings, recent guidelines suggest that women at very high fracture risk should be considered for sequential treatment, i.e., a treatment starting with an anabolic agent, followed by an antiresorptive agent [47,48]. Thus, with adequate identification of women at high or very high risk and with appropriate pharmacological intervention, a substantial proportion of fragility fractures could be prevented.

The discrepancy between eligible patients and patients actually treated is known as the treatment gap. In the European Union and in the Unites States, only a small proportion of women eligible for pharmacological treatment are being prescribed osteoporosis medication. In the EU6 countries, the average treatment gap (percent of eligible patients not treated) was 73% for women and 63% for men in year 2017 [23]. In the United States, the use of osteoporosis medications in patients following a hip fracture declined from over 40% in 2002 to about 20.5% in 2011 [49]. A recent population-based Swedish study of older women 75–80-year-old, revealed that less than 22% of women with treatment indication according to national guidelines were being treated with osteoporosis medication [50].

*Secondary fracture prevention*

Large meta-analyses have shown that individuals who have sustained a fracture have about double the risk of a subsequent fracture as compared to their fracture free peers [51,52]. Postmenopausal women with vertebral fractures have particularly high risk of subsequent fractures, and for new additional vertebral fractures the risk is increased over 4 times [53]. Of those with hip fracture, about half have previously sustained another fracture [54], suggesting that preventive measures targeted at patients with other fractures could be a valuable option to prevent the most serious fracture, the hip fracture.

The risk increase after fracture is not constant over time, but is markedly elevated (by about 4-5 times) in the two first years following the index fracture, emphasizing the importance of identifying fracture patients and intervening to reduce the risk of subsequent fracture, early after the index fracture [55,56].

Secondary prevention programs called Fracture Liaison Services (FLS) have to some extent been implemented worldwide with the aim of reducing the treatment gap after a fragility fracture. To facilitate implementation and to uphold adequate care quality, Clinical Quality Standards for FLS have been developed in the United Kingdom, New Zeeland and Canada [57-59]. Internationally endorsed clinical standards have also been developed by the International Osteoporosis Foundation (IOF) in the Capture the Fracture Program [60]. Patients included in FLS services have higher rates of evaluation with BMD assessment and treatment initiation as well as better adherence to pharmacological treatment [61,62]. However, data on the effect of FLS on rates of recurrent fractures have been very limited. A large study investigating the risk of subsequent fracture after a first fragility fracture in patients treated at hospitals, with and without an FLS, in Western Sweden was recently presented. Patients cared for at hospitals with a FLS were much more likely to be evaluated with BMD testing, receive osteoporosis medication, and had 18% lower risk of recurrent fracture, than historic controls and patients treated at hospitals without FLS during the same time-period [63].

*Primary fracture prevention*

The proportion of women that might be targeted for primary prevention differs substantially by country, due to the large differences in prevalence of fragility fracture in women 50 years or older in different countries. For example, 90% of women in this age group would be eligible for screening in France while the corresponding proportion in Sweden would only be 77% [64,65]. Different case-finding strategies to identify women at high risk, due to presence of risk factors such as use of oral glucocorticoids, heredity for osteoporosis or fracture, smoking, or diseases causing secondary osteoporosis, who have not yet fractured have been proposed [66-69]. The fracture risk assessment tool FRAX® is the most widely used such model globally [70], and incorporates several important risk factors, with or without femoral neck BMD, for fracture and provides the 10-year probability of MOF and hip fracture in women and men, 40-90 years old. The FRAX® tool can be used to identify women and men at high risk for fracture so that further evaluation can with BMD testing and preventive measures can be instituted.

The UK National Osteoporosis Guideline Group (NOGG) has based its guidance on FRAX®, with utilization of a FRAX® intervention threshold at a fracture probability equal to the probability of a woman with a previous fracture [71]. The National Osteoporosis Foundation in the United States, recommends osteoporosis medication for postmenopausal women with 1) a previous hip or spine fracture, 2) a T-score of -2.5 SD or less at the hip, femoral neck or spine, 3) a T-score at these sites of -1 to -2.5 SD (osteopenia) and a 10-year probability of MOF or hip fracture of ≥20% or ≥3%, respectively, according to the United States-adapted FRAX® tool [72].

Until recently, the effectiveness of risk-assessment strategies in which samples of the general population might be evaluated for risk factors and BMD estimation to derive individual estimates of absolute fracture risk, with targeting of anti-osteoporosis therapy on the basis of these estimates, remained uncertain. The publication of the MRC SCOOP trial (SCreening of Older wOmen for the Prevention of fractures) provides strong support for such a strategy [73]. Over 5 years, compared to standard clinical care, the screening program reduced the number of hip fractures by 28%. Similar results were observed in a study from Denmark [74] but with lesser effects observed in a further study in the Netherlands [75]. A meta-analysis of the three trials showed that screening reduced hip fracture risk by 20% [76].

**Concluding remarks**

Bone fragility and the resulting fractures are very common in postmenopausal women and projections indicate that due to the ageing population, an increase in the number of osteoporotic fractures, accompanied by substantially increased DALYs and financial costs, are to be expected globally. Secondary fracture prevention, orchestrated via implementation of FLS, so that a growing proportion of women at risk are evaluated and treated with osteoporosis medications, is a crucial step in reducing fracture numbers. In addition, established primary prevention strategies, based on case-finding methods utilizing fracture prediction tools, such as FRAX®, to identify women without fracture, but with elevated risk, could be increasingly used, in order to further reduce fracture numbers.

**References**

1. Osteoporosis prevention, diagnosis, and therapy. Jama. 2001 Feb 14;285(6):785-95.

2. Lorentzon M, Cummings SR. Osteoporosis: the evolution of a diagnosis. J Intern Med. 2015 Jun;277(6):650-61.

3. Cheng XG, Lowet G, Boonen S, et al. Assessment of the strength of proximal femur in vitro: relationship to femoral bone mineral density and femoral geometry. Bone. 1997 Mar;20(3):213-8.

4. Johnell O, Kanis JA, Oden A, et al. Predictive value of BMD for hip and other fractures. J Bone Miner Res. 2005 Jul;20(7):1185-94.

5. Kanis JA, Melton LJ, 3rd, Christiansen C, et al. The diagnosis of osteoporosis. J Bone Miner Res. 1994 Aug;9(8):1137-41.

6. Kanis JA, McCloskey EV, Johansson H, et al. A reference standard for the description of osteoporosis. Bone. 2008 Mar;42(3):467-75.

7. Khosla S, Melton LJ, 3rd, Riggs BL. The unitary model for estrogen deficiency and the pathogenesis of osteoporosis: is a revision needed? J Bone Miner Res. 2011 Mar;26(3):441-51.

8. Kanis JA, Oden A, Johnell O, et al. The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int. 2001;12(5):417-27.

9. Warriner AH, Patkar NM, Curtis JR, et al. Which fractures are most attributable to osteoporosis? J Clin Epidemiol. 2011 Jan;64(1):46-53.

10. Kanis JA, Johnell O, Oden A, et al. Long-term risk of osteoporotic fracture in Malmo. Osteoporos Int. 2000;11(8):669-74.

11. Gerdhem P. Osteoporosis and fragility fractures: Vertebral fractures. Best Pract Res Clin Rheumatol. 2013 Dec;27(6):743-55.

12. Bliuc D, Nguyen TV, Eisman JA, et al. The impact of nonhip nonvertebral fractures in elderly women and men. J Clin Endocrinol Metab. 2014 Feb;99(2):415-23.

13. Johnell O, Kanis JA, Oden A, et al. Mortality after osteoporotic fractures. Osteoporos Int. 2004 Jan;15(1):38-42.

14. Cooper C, Campion G, Melton LJ, 3rd. Hip fractures in the elderly: a world-wide projection. Osteoporos Int. 1992 Nov;2(6):285-9.

15. Kanis JA. Assessment of osteoporosis at the primary health

care level. In WHO Scientific Group (ed) WHO Scientific group

Technical Report. World Health Organization; 2007. p. 103.

16. Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int. 2006 Dec;17(12):1726-33.

17. Jordan KM, Cooper C. Epidemiology of osteoporosis. Best Pract Res Clin Rheumatol. 2002 Dec;16(5):795-806.

18. Dennison EM, Sayer AA, Cooper C. Epidemiology of sarcopenia and insight into possible therapeutic targets. Nat Rev Rheumatol. 2017 Jun;13(6):340-347.

19. Sambrook P, Cooper C. Osteoporosis. Lancet. 2006 Jun 17;367(9527):2010-8.

20. Kanis JA, Oden A, McCloskey EV, et al. A systematic review of hip fracture incidence and probability of fracture worldwide. Osteoporos Int. 2012 Sep;23(9):2239-56.

21. Pisani P, Renna MD, Conversano F, et al. Major osteoporotic fragility fractures: Risk factor updates and societal impact. World J Orthop. 2016 Mar 18;7(3):171-81.

22. Jakobsen A, Laurberg P, Vestergaard P, et al. Clinical risk factors for osteoporosis are common among elderly people in Nuuk, Greenland. Int J Circumpolar Health. 2013;72:19596.

23. Borgstrom F, Karlsson L, Ortsater G, et al. Fragility fractures in Europe: burden, management and opportunities. Arch Osteoporos. 2020 Apr 19;15(1):59.

24. Hippisley-Cox J, Coupland C, Robson J, et al. Derivation, validation, and evaluation of a new QRISK model to estimate lifetime risk of cardiovascular disease: cohort study using QResearch database. BMJ. 2010 Dec 9;341:c6624.

25. Johansson L, Sundh D, Nilsson M, et al. Vertebral fractures and their association with health-related quality of life, back pain and physical function in older women. Osteoporos Int. 2018 Jan;29(1):89-99.

26. Sernbo I, Johnell O. Consequences of a hip fracture: a prospective study over 1 year. Osteoporos Int. 1993 May;3(3):148-53.

27. Adib Hajbaghery M, Abbasinia M. Quality of life of the elderly after hip fracture surgery: a case-control study. J Caring Sci. 2013 Mar;2(1):53-9.

28. Center JR, Nguyen TV, Schneider D, et al. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet. 1999 Mar 13;353(9156):878-82.

29. Johansen A, Mansor M, Beck S, et al. Outcome Following Hip Fracture: Long Term Mortality and Post-Discharge Residence. Osteoporosis Int. 2012 Jul;23:S545-S545.

30. Organization WH. Metrics: disability-adjusted life years (DALY). WHO; 2018 [cited 2017 12/10/2017]. Available from: <http://www.who.int/healthinfo/global_burden_disease/metrics_daly/en/>

31. GBD compare data visualization.: Institute for Health Metrics and Evaluation (IHME); 2016. Available from: <https://vizhub.healthdata.org/gbdcompare/>

32. Melton LJ, 3rd, Gabriel SE, Crowson CS, et al. Cost-equivalence of different osteoporotic fractures. Osteoporos Int. 2003 Jun;14(5):383-8.

33. Williamson S, Landeiro F, McConnell T, et al. Costs of fragility hip fractures globally: a systematic review and meta-regression analysis. Osteoporosis Int. 2017 2017/10/01;28(10):2791-2800.

34. Ballane G, Cauley JA, Luckey MM, et al. Secular Trends in Hip Fractures Worldwide: Opposing Trends East Versus West. Journal of Bone and Mineral Research. 2014;29(8):1745-1755.

35. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007 May 3;356(18):1809-22.

36. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA. 1999 Oct 13;282(14):1344-52.

37. Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int. 2000;11(1):83-91.

38. Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med. 1995 Nov 30;333(22):1437-43.

39. Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009 Aug 20;361(8):756-65.

40. Bone HG, Wagman RB, Brandi ML, et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 2017 Jul;5(7):513-523.

41. Miller PD, Hattersley G, Riis BJ, et al. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial. Jama. 2016 Aug 16;316(7):722-33.

42. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001 May 10;344(19):1434-41.

43. Finkelstein JS, Wyland JJ, Lee H, et al. Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis. J Clin Endocrinol Metab. 2010 Apr;95(4):1838-45.

44. Cosman F, Crittenden DB, Adachi JD, et al. Romosozumab Treatment in Postmenopausal Women with Osteoporosis. N Engl J Med. 2016 Oct 20;375(16):1532-1543.

45. Kendler DL, Marin F, Zerbini CAF, et al. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. 2018 Jan 20;391(10117):230-240.

46. Saag KG, Petersen J, Brandi ML, et al. Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis. N Engl J Med. 2017 Oct 12;377(15):1417-1427.

47. Kanis JA, Harvey NC, McCloskey E, et al. Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures. Osteoporos Int. 2020 Jan;31(1):1-12.

48. Lorentzon M. Treating osteoporosis to prevent fractures: current concepts and future developments. J ntern Med. 2019 Apr;285(4):381-394.

49. Solomon DH, Johnston SS, Boytsov NN, et al. Osteoporosis medication use after hip fracture in U.S. patients between 2002 and 2011. J Bone Miner Res. 2014 Sep;29(9):1929-37.

50. Lorentzon M, Nilsson AG, Johansson H, et al. Extensive undertreatment of osteoporosis in older Swedish women. Osteoporos Int. 2019 Jun;30(6):1297-1305.

51. Klotzbuecher CM, Ross PD, Landsman PB, et al. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res. 2000 Apr;15(4):721-39.

52. Kanis JA, Johnell O, De Laet C, et al. A meta-analysis of previous fracture and subsequent fracture risk. Bone. 2004 Aug;35(2):375-82.

53. Lindsay R, Silverman SL, Cooper C, et al. Risk of new vertebral fracture in the year following a fracture. Jama. 2001 Jan 17;285(3):320-3.

54. Port L, Center J, Briffa NK, et al. Osteoporotic fracture: missed opportunity for intervention. Osteoporos Int. 2003 Sep;14(9):780-4.

55. van Geel TA, van Helden S, Geusens PP, et al. Clinical subsequent fractures cluster in time after first fractures. Ann Rheum Dis. 2009 Jan;68(1):99-102.

56. Johansson H, Siggeirsdottir K, Harvey NC, et al. Imminent risk of fracture after fracture. Osteoporos Int. 2017 Mar;28(3):775-780.

57. Canada O. Quality Standards for Fracture Liaison Services in Canada. Osteoporosis Canada. Toronto2014.

58. Zealand. ON. Clinical Standards for Fracture Liaison Services in New Zealand. Wellington2016.

59. Gittoes N, McLellan A, Cooper A. Effective Secondary Prevention of Fragility Fractures: Clinical Standards for Fracture Liaison Services. Camerton: National Osteoporosis Society; 2015.

60. Akesson K, Marsh D, Mitchell PJ, et al. Capture the Fracture: a Best Practice Framework and global campaign to break the fragility fracture cycle. Osteoporos Int. 2013 Aug;24(8):2135-52.

61. Ganda K, Puech M, Chen JS, et al. Models of care for the secondary prevention of osteoporotic fractures: a systematic review and meta-analysis. Osteoporos Int. 2013;24(2):393-406.

62. Wu CH, Tu ST, Chang YF, et al. Fracture liaison services improve outcomes of patients with osteoporosis-related fractures: A systematic literature review and meta-analysis. Bone. 2018 Jun;111:92-100.

63. Axelsson KF, Johansson H, Lundh D, et al. Association Between Recurrent Fracture Risk and Implementation of Fracture Liaison Services in Four Swedish Hospitals: A Cohort Study. J Bone Miner Res. 2020 Jul;35(7):1216-1223.

64. Gauthier A, Kanis JA, Martin M, et al. Development and validation of a disease model for postmenopausal osteoporosis. Osteoporos Int. 2011 Mar;22(3):771-80.

65. Cawston H, Maravic M, Fardellone P, et al. Epidemiological burden of postmenopausal osteoporosis in France from 2010 to 2020: estimations from a disease model. Arch Osteoporos. 2012;7:237-46.

66. Axelsson KF, Nilsson AG, Wedel H, et al. Association Between Alendronate Use and Hip Fracture Risk in Older Patients Using Oral Prednisolone. JAMA. 2017 Jul 11;318(2):146-155.

67. Kanis JA, Johansson H, Oden A, et al. A Meta-Analysis of Prior Corticosteroid Use and Fracture Risk. Journal of Bone and Mineral Research. 2004;19(6):893-899.

68. Kanis JA, Johnell O, Oden A, et al. Smoking and fracture risk: a meta-analysis. Osteoporos Int. 2005 Feb;16(2):155-62.

69. Kanis JA, Johansson H, Oden A, et al. A family history of fracture and fracture risk: a meta-analysis. Bone. 2004 Nov;35(5):1029-37.

70. Kanis JA, Harvey NC, Johansson H, et al. A decade of FRAX: how has it changed the management of osteoporosis? Aging Clin Exp Res. 2020 Feb;32(2):187-196.

71. Compston J, Bowring C, Cooper A, et al. Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013. Maturitas. 2013 Aug;75(4):392-6.

72. Cosman F, de Beur SJ, LeBoff MS, et al. Clinician's Guide to Prevention and Treatment of Osteoporosis. Osteoporos Int. 2014 Oct;25(10):2359-81.

73. Shepstone L, Lenaghan E, Cooper C, et al. Screening in the community to reduce fractures in older women (SCOOP): a randomised controlled trial. Lancet. 2018 Feb 24;391(10122):741-747.

74. Rubin KH, Rothmann MJ, Holmberg T, et al. Effectiveness of a two-step population-based osteoporosis screening program using FRAX: the randomized Risk-stratified Osteoporosis Strategy Evaluation (ROSE) study. Osteoporos Int. 2018 Mar;29(3):567-578.

75. Merlijn T, Swart KM, van Schoor NM, et al. The Effect of a Screening and Treatment Program for the Prevention of Fractures in Older Women: A Randomized Pragmatic Trial. J Bone Miner Res. 2019 Nov;34(11):1993-2000.

76. Merlijn T, Swart KMA, van der Horst HE, et al. Fracture prevention by screening for high fracture risk: a systematic review and meta-analysis. Osteoporos Int. 2020 Feb;31(2):251-257.

77. Kanis JA, McCloskey EV, Johansson H, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2013 Jan;24(1):23-57.

**Figures**




Figure 1. Age-specific incidence of vertebral, hip, and forearm fractures in women from Sweden. Figure compiled from data in [8].




Figure 2. Age-standardised annual incidence of hip fractures in women (/100,000) according to country together with the colour codes to denote moderate, high and very high risk [20].




Figure 3. DALYs by disease in EU6 in 17 selected non-communicable diseases [23].

**Table**

**Table 1** Antifracture efficacy of the most frequently used treatments for postmenopausal osteoporosis when given with calcium and vitamin D, as derived from randomized controlled trials (updated from [77]).

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | Effect on vertebral fracture risk | |  | Effect on non-vertebral fracture risk | |
|  | Osteoporosis | Established osteoporosisa |  | Osteoporosis | Established osteoporosisa |
| Alendronate | + | + |  | NA | + (including hip) |
| Risedronate | + | + |  | NA | + (including hip) |
| Ibandronate | NA | + |  | NA | + b |
| Zoledronic acid | + | + |  | NA | + c |
| HRT | + | + |  | + | + (including hip) |
| Raloxifene | + | + |  | NA | NA |
| Teriparatide | NA | + |  | NA | + |
| Denosumab | + | + c |  | + (including hip) | + c |

*NA* no evidence available, + effective drug

a Women with a prior vertebral fracture

b In subsets of patients only (post hoc analysis)

c Mixed group of patients with or without prevalent vertebral fractures

HRT=Hormone Replacement Therapy.